Recent guidance documents for managing major depression, Barrett's esophagus, and CRC screening, give either no mention or neutral mention to the addition of molecular diagnostics.
____
In the October 2022 Annals of Internal Medicine, discussion of a new DOD/VA guidance document for major depression. Evidence for pharmacogenetic testing in depression is rating as too equivocal to evaluate to a conclusion.
The VA/DOD guideline in full, is here:
https://www.healthquality.va.gov/guidelines/MH/mdd/index.asp
The summary by McQuaid et al. is here:
https://www.acpjournals.org/doi/10.7326/M22-1603
###
A 2022 review of Barrett's esophagus, diagnosis and management, in JAMA does not mention molecular diagnostics. Sharma 2022:
https://jamanetwork.com/journals/jama/fullarticle/2795263
Similarly, a 2022 guidance document in Amer J Gastroenterol by Shaheen et al. does not recommend molecular testing:
###
A new 2022 review article on "How would you screen for CRC?" in Annals of Internal Medicine notes that one of the available methods is stool-based DNA-FIT, but does not provide any directional recommendation for using this much-more-expensive technology over other basic FIT technology. Burns et al.:
https://www.acpjournals.org/doi/10.7326/M22-1961
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.